Annual Statements Open main menu

GENETHERA INC - Quarter Report: 2008 March (Form 10-Q)

SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q


[ X ]    Quarterly Report pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


For the Quarterly Period Ended March 31, 2008


Commission File No. 000-27237


GENETHERA, INC.

(Exact name of small Business Issuer as specified in its Charter)


Nevada                                   65-0622463


(State or Other Jurisdiction of              (I.R.S. Employer

Incorporation or Organization)            Identification Number)


3930 Youngfield Street, Wheat Ridge CO              80033

(Address of principal executive offices)          (Zip Code)


Issuer's telephone number, including area code:   (303) 463-6371



Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days [ X ] Yes [ ] No


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.  (Check one):

Large accelerated filer  [  ]

Accelerated filer  [ X ]

Non-accelerated filer  [  ]

Smaller reporting company  [  ]

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):  

Yes  [  ]

No  [ X ]


State the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 56,493,749 Shares of $.001 par value Common Stock outstanding as of March 31, 2008 and Series A 4,600 Shares, and Series B 3,000,000 shares of $.001 par value Preferred Stock outstanding as of March 31, 2008.







                        PART 1 - FINANCIAL INFORMATION


Item 1. Financial Statements












GENETHERA, INC.

AND SUBSIDIARY

(A Development Stage Company)

CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2008

UNAUDITED
































GENETHERA, INC. AND SUBSIDIARY

A DEVELOPMENT STAGE COMPANY

CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2008

UNAUDITED














TABLE OF CONTENTS






Page No.


Report of Independent Registered Public Accounting Firm

2

Consolidated Balance Sheet March 31, 2008  

3

 

 

Consolidated Statements of Operations for March 31, 2008 and 2007

5

 

 

Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the Period ended March 31, 2008

6

 

 

Consolidated Statements of Cash Flows for March 31, 2008 and 2007

7

 

 

Notes to Consolidated Financial Statements

8






























Balance Sheet  


GENETHERA, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEET

UNAUDITED 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Unaudited

 

 

 

March 31, 2008

 

December 31, 2007

 

 

 

 

Current Assets

 

 

 

Cash

 $                              1

 

 $                             196

Accounts receivable - less reserve for uncollectible amount

                             822

 

                           68,267

 

 

 

 

Total Current Assets

                             823

 

                           68,463

 

 

 

 

Property and equipment

                       727,428

 

                         727,428

Accumulated Depreciation

                     (454,804)

 

                        (436,864)

Property and equipment, net

                       272,624

 

                         290,564

 

 

 

 

Other Assets

 

 

 

Deposits

                          5,278

 

                             5,278

 

 

 

 

Total Other Assets

                          5,278

 

                             5,278

 

   

 

 

 

 

 

 

Total Assets

 $                    278,725

 

 $                       364,305

 

 

 

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Unaudited

 

Year End

 

March 31, 2008

 

December 31, 2007

 

 

 

 

Current Liabilities

 

 

 

Accounts payable

 $                    594,115

 

 $                       582,869

Accrued expenses

                    1,031,113

 

                         968,702

 

 

 

 

   Notes  payable

                         80,086

 

                         150,290

 

 

 

 

Total Current Liabilities

                    1,705,314

 

                       1,701,861

 

 

 

 

 

 

 

 

Total Liabilities

                    1,705,314

 

                       1,701,861

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' Equity

 

 

 

Preferred stock, $.001 par value, 20,000,000 shares authorized;

   

 

 

Series A 4,600 shares issued and outstanding $.001 par value

                                5

 

5

Series B 3,000,000 shares issued and outstanding $.001 par value

                          3,000

 

3,000

Common stock $.001 par value, 100,000,000 shares authorized;

 

 

 

56,494,749 shares issued and outstanding

                         56,496

 

51,527

Additional paid in capital

                   15,113,572

 

15,017,704

Deficit accumulated during development stage

                 (16,599,661)

 

(16,409,792)

 

 

 

 

Total Stockholders' Equity

                   (1,426,588)

 

                     (1,337,556)

 

 

 

 

 

 

 

 

Total Liabilities &  Stockholders' Equity

 $                    278,726

 

 $                       364,305

 

 

 

 

 

 

 

 

 

 

 

 

 

 $                              1

 

 



 



Statements of Operations


GENETHERA, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS

FOR THE PERIOD FROM OCTOBER 5, 1998 (INCEPTION) TO MARCH 31, 2008

UNAUDITED


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the period from

 

 

 

3 month period ended March 31,

 

October 5, 1998

 

 

 

2008

 

2007

 

(inception) to

 

 

 

 

 

 

 

March 31, 2008

 

 

Income

 

 

 

 

 

 

 

Sales

 $                 10,821

 

 $                         -   

 

 $                       527,470

 

          516,649.00

Research fees

                          -   

 

                            -   

 

                          188,382

 

          188,382.00

Total income

                   10,821

 

                            -   

 

                          715,852

 

          705,031.00

 

 

 

 

 

 

 

 

Cost of sales

                          -   

 

                            -   

 

                          (30,352)

 

           (30,352.00)

 

 

 

 

 

 

 

 

Gross profit

                   10,821

 

                            -   

 

                          685,500

 

          674,679.00

 

 

 

 

 

 

 

 

Expenses

 

 

 

 

 

 

 

Other compensation

                       -   

 

                            -   

 

                        3,283,009

 

       3,283,009.00

Consulting

                52,560

 

                     46,601

 

                        4,873,154

 

       4,820,594.00

   General and administrative expenses

                   61,196

 

                     96,399

 

                        3,947,883

 

       3,886,687.00

Payroll expenses

                58,500

 

                     58,500

 

                        2,163,119

 

       2,104,619.00

   Depreciation

                   17,940

 

                     18,251

 

                          454,804

 

          436,864.00

Settlement expense

                          -   

 

                            -   

 

                            82,625

 

            82,625.00

Impairment of long-lived asset

                       -   

 

                            -   

 

                            55,714

 

            55,714.00

Bad debt expense

                10,367

 

 

 

 

 

 

Lab expenses

                     127

 

                            -   

 

                            16,107

 

            15,980.00

Total expenses

                  200,690

 

                    219,751

 

                      15,171,155

 

                         -   

 

 

 

 

 

 

 

     15,019,535.00

Loss from operations

                (189,869)

 

                  (219,751)

 

                    (14,485,655)

 

 

 

 

 

 

 

 

 

    (14,344,856.00)

Other income (expenses)

 

 

 

 

 

 

 

Beneficial conversion expense

                          -   

 

                            -   

 

                                  -   

 

 

Interest expense

                       -   

 

                            -   

 

                      (1,987,991)

 

      (1,987,991.00)

Gain on settlements

                       -   

 

                            -   

 

                          (46,758)

 

           (46,758.00)

Other income (expenses), net

                       -   

 

                            -   

 

                            58,203

 

            58,203.00

 

 

 

 

 

 

 

            33,675.00

Net loss from continuing operations

                (189,869)

 

                  (219,751)

 

                    (16,462,201)

 

 

Gain (loss) from disposal of subs

 

 

 

 

                                  -   

 

       (16,287,727.00)

Loss from discontinued operations

                          -   

 

                              -

 

                         (122,065)

 

           (122,065.00)

 

 

 

 

 

 

 

 

Net loss

 $             (189,869)

 

 $               (219,751)

 

 $                  (16,584,263)

 

         (16,409,792)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per common share Basic & Diluted

 $                 (0.004)

 

 $                   (0.006)

 

 

 

 

 

 

 

 

 

 

 

 

Weight Average Shares

             53,541,996

 

               56,493,749

 

 

 

 



 Changes in Stockholders Equity



GENETHERA, INC. AND SUBSIDIARY

(CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE PERIOD ENDED MARCH 31, 2008

UNAUDITED



 

 

 

 

 

 

 

 

 

Development

 

 

 

 

 

 

 

 

 

 

Stage

 

 

Preferred Stock A

Preferred Stock B

Common Stock

Paid in

Subscription

Accumulated

 

 

Shares

Amount

Shares

Amount

Shares

Amount

Capital

Agreement

     Deficit     

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance December 31, 2007

          4,600

 $         5

  3,000,000

 $   3,000

       51,525,849

 $    51,527

 $    15,017,704

 $                   -   

 $       (16,409,792)

         (1,337,556)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares issued for consulting services

 

 

 

 

         4,250,763

         4,251

              82,223

 

 

                86,474

 

 

 

 

 

 

 

 

 

 

                        -   

Shares issued for rent

 

 

 

 

            718,137

            718

              13,645

 

 

                14,363

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss March 31, 2008

 

 

 

 

 

 

 

 

               (189,869)

            (189,869)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance March 31, 2008

          4,600

 $         5

  3,000,000

 $   3,000

       56,494,749

 $    56,496

 $    15,113,572

 $                   -   

 $       (16,599,661)

 $      (1,426,588)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 



Cash Flows  


GENETHERA, INC. AND SUBIDIARY

(DEVELOPMENT STAGE COMPANY)

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE PERIOD FROM OCTOBER 5, 1998 (INCEPTION FOR MARCH 31, 2008)

UNAUDITED




 

 

 

 

 

For the period from

 

 

 

3 month period ended March 31,

 

October 5, 1998

 

 

 

 

 

 

 

(inception) to

 

 

 

2008

 

2007

 

March 31, 2008

 

 

 

 

 

 

 

 

 

2007

 

 

 

 

 

 

 

 

Cash flows from operating activities:

 

 

 

 

 

 

 

  Net loss

 $                   (189,869)

 

 $           (219,751)

 

 $              (16,633,333)

 

 $                 (16,443,464)

 

 

 

 

 

 

 

 

  Adjustments to reconcile net loss to net

 

 

 

 

 

 

 

    cash provided by (used in) operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

                         17,940

 

                 18,251

 

255,971.0

 

                         238,031

Bad Debt expense

                         10,367

 

                (90,000)

 

10,367.0

 

                                 -   

Compensation in exchange for common stock

                        100,836

 

                 89,960

 

9,061,147.0

 

                       8,960,311

Beneficial conversion feature

 

 

 

 

1,987,990.0

 

                       1,987,990

Changes in operating assets and liabilities

 

 

 

 

 

 

 

(Increase) Decrease in:

 

 

 

 

 

 

 

Accounts receivable

                         67,445

 

                 93,100

 

-62,289.0

 

                        (129,734)

Accounts receivable Related Parties

                                -   

 

                   8,906

 

17,390.0

 

                           17,390

      Reserve for Uncollectible

                        (10,367)

 

                       -   

 

-100,367.0

 

                          (90,000)

Inventory

                                -   

 

                       -   

 

0.0

 

                                 -   

Prepaid expenses

                                -   

 

                    (110)

 

-110.0

 

                              (110)

Other assets

                                -   

 

                       -   

 

7,278.0

 

                             7,278

Increase in accounts payable

 

 

 

 

 

 

 

and accrued liabilites

                         73,657

 

                 92,950

 

1,794,613.0

 

                       1,720,956

 

 

 

 

 

 

 

 

      Total adjustments

                        259,878

 

               213,057

 

                  12,971,990

 

                     12,892,112

 

 

 

 

 

 

 

 

  Net cash used in operating activities

                         70,009

 

                 (6,695)

 

                  (3,661,343)

 

                     (2,865,548)

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

  Cash payments for the purchase of property

                                -   

 

                       -   

 

                     (299,072)

 

                        (299,072)

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

   Bank overdraft

 

 

 

 

                              -   

 

                                 -   

Capital contributed as equipment

 

 

 

 

                      272,376

 

                         272,376

Principal payments on notes & leases payable

 

 

 

 

                     (240,119)

 

                        (240,119)

Payment of lease payable

                                -   

 

                 (5,834)

 

                      120,343

 

                         120,343

Payment for Accrued Salaries

 

 

                       -   

 

                      189,350

 

                         189,350

Proceeds from issuance of  stock

                                -   

 

                       -   

 

                    1,908,882

 

                       1,908,882

Proceeds from loans payable

                        (70,204)

 

                 12,518

 

                    1,562,586

 

                       1,632,790

Proceeds from Subscription Recievable

                                -   

 

 

 

                      100,040

 

                         100,040

Repurchase of Common Stock

                                -   

 

 

 

                        (1,610)

 

                           (1,610)

Reciept of APIC

                                -   

 

 

 

                        20,000

 

                           20,000

Payment of Perfered Dividends

                                -   

 

 

 

                      (46,338)

 

                          (46,338)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Net cash provided by financing activities

                        (70,204)

 

                   6,684

 

                    3,885,510

 

                       3,955,714

 

 

 

 

 

 

 

 

Net increase (decrease) in cash

                            (195)

 

                      (11)

 

                      (74,905)

 

                         791,094

 

 

 

 

 

 

 

 

Cash, beginning of year

                              196

 

                     234

 

                              -   

 

                                 -   

 

 

 

 

 

 

 

 

Cash, end of year

 $                              1

 

 $                   224

 

 $                             1

 

 $                             196

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

 

 

Cash paid during the period for interest expense

0

 

0

 

 $                     46,758

 

 $                        46,758

Cash paid during the period for Taxes

$0

 

$0

 

 $                           -   

 

 $                               -   

 

 

 

 

 

 

 

 



GENETHERA, INC. AND SUBSIDIARY

A DEVELOPMENT STAGE COMPANY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2008

UNAUDITED




NOTE 1  

PRINCIPLES OF CONSOLIDATION


Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, GeneThera, Inc. (Colorado). All significant inter-company balances and transactions have been eliminated.



NOTE 2  

BASIS OF PRESENTATION


The interim financial information included herein is unaudited; however, such information reflects all adjustments which are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations, changes in stockholders’ equity (deficit) and cash flows for the interim periods.  All such adjustments are of a normal, recurring nature.  The results of operations for the first three months of the year are not necessarily indicative of the results of operations which might be expected for the entire year.  


The accompanying consolidated financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and, therefore, omit or condense certain footnotes and other information normally included in financial statements prepared in accordance with generally accepted accounting principles.  It is suggested that these condensed financial statements should be read in conjunction with the Company's financial statements and notes thereto included in the Company's audited financial statements on Form 10-KSB/A as amended for the fiscal year ended December 31, 2007.



NOTE 3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES


Stock Based Compensation


The Company has adopted the use of Statement of Financial Accounting Standards No. 123R , “Share-Based Payment”, (SFAS No. 123R)   This Statement requires an entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). That cost is recognized over the period during which an employee is required to provide service in exchange for the award—the requisite service period (usually the vesting period). No compensation cost is recognized for equity instruments for which employees do not render the requisite service.   This Statement supersedes APB Opinion No. 25, “Accounting for Stock Issued to Employees”, and its related implementation guidance and eliminates the alternative to use Opinion 25’s intrinsic value method of accounting that was provided in Statement 123 as originally issued.  



GENETHERA, INC. AND SUBSIDIARY

A DEVELOPMENT STAGE COMPANY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2008

UNAUDITED



NOTE 3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES – continued



Earnings per Share

Basic earnings per share are computed based on the weighted average number of common shares outstanding during each year.  Diluted earnings per share are computed based on the weighted average number of common shares outstanding during the period.  



NOTE 4

PROPERTY AND EQUIPMENT


Property and equipment consisted of the following:

March 31, 2008


Computers

$   42,987

Office Equipment

39,891

Furniture & fixtures

1,465

Laboratory equipment

  643,084

 

 

 

727,428

Less accumulated depreciation

(454,804 )

 

 

 

$272,624


Depreciation expense for the three months ended March 31, 2008 and 2007 was $17,940 and $18,251 respectively.




GENETHERA, INC. AND SUBSIDIARY

A DEVELOPMENT STAGE COMPANY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2008

UNAUDITED



NOTE 5

STOCKHOLDERS’ EQUITY


Common Stock


In January 2008, the Company issued 1,734,524 shares valued at $34,690 to consulting services of operations and resulted in an immediate charge to operations.


In February 2008, the Company issued 646,834 shares valued at $14,375 to consulting services of operations and resulted in an immediate charge to operations.


In February 2008, the Company issued 218,136 shares valued at $4,363 for rent of the facility of operations and resulted in an immediate charge to operations.


In March 2008, the Company issued 1,870,405 shares valued at $37,408 to consulting services of operations and resulted in an immediate charge to operations.


In March 2008, the Company issued 500,001 shares valued at $10,000 for rent and yearly maintenance of the facility of operations and resulted in an immediate charge of operations.


As of March 31, 2008, there were 56,494,749 shares of our common stock issued and outstanding.  


Preferred Stock


As of March 31, 2008, there were 4,600 shares of our Series A, Convertible Preferred Stock (“Series A”) issued and outstanding, and 3,000,000 shares of our Series B, Convertible Preferred Stock (“Series B”) were issued and outstanding.


NOTE 6          GOING CONCERN UNCERTAINTY


These financial statements are presented assuming the Company will continue as a going concern.  For the periods ended March 31, 2008 and 2007, the Company showed operating losses of $189,869 and $219,751 respectively. The accompanying financial statements indicate that current liabilities exceed current assets by $1,704,491for the three months ended March 31, 2008.

These factors raise substantial doubt about its ability to continue as a going concern.  Management’s plan with regard to these matters includes raising working capital and significant assets and resources to assure the Company’s viability, through private or public equity offering, and/or debt financing, and/or through the acquisition of new business or private ventures.












Item 2. Management's Discussion and Analysis and Results of Operation


The following discussion and analysis should be read in conjunction with the financial statements and notes thereto that appear elsewhere herein.


FORWARD-LOOKING AND CAUTIONARY STATEMENTS


Sections of this Form 10-Q, including the Management's Discussion and Analysis or Plan of Operation, contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), Section 21E of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to risks and uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements. You should not unduly rely on these statements. Forward-looking statements involve assumptions and describe our plans, strategies, and expectations. You can generally identify a forward-looking statement by words such as "may," "will," "should," “would," could," "plan," "goal," "potential," "expect," "anticipate," "estimate," "believe," "intend," "project," and similar words and variations thereof. This report contains forward-looking statements that address, among other things,


* our financing plans,

* regulatory environments in which we operate or plan to operate, and

* trends affecting our financial condition or results of operations, the impact of competition, the start-up of certain operations and acquisition opportunities.


Factors, risks, and uncertainties that could cause actual results to differ materially from those in the forward-looking statements ("Cautionary Statements") include, among others,


* our ability to raise capital,

* our ability to execute our business strategy in a very competitive environment,

* our degree of financial leverage,

* risks associated with our acquiring and integrating companies into our own,

* risks relating to rapidly developing technology,

* regulatory considerations;

* risks related to international economies,

* risks related to market acceptance and demand for our products and services,

* the impact of competitive services and pricing, and

* other risks referenced from time to time in our SEC filings.


All subsequent written and oral forward-looking statements attributable to us, or anyone acting on our behalf, are expressly qualified in their entirety by the cautionary statements. We do not undertake any obligations to publicly release any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect unanticipated events that may occur.


RESULTS OF OPERATIONS


Gross profits for the three-month period ended March 31, 2008 were ($189,869) compared to ($219,751) for the same period last year. Personnel (salaries) stay the same from $58,500 for the prior three month period ending March 31, 2007 to $58,500 for the three month period ending March 31, 2008.  Professional expenses (consulting and professional fees) comparing the three month period ending March 31, 2008, to the three month period ending March 31, 2007, increased from $46,601 to $52,560 with the decrease attributable to the consultants throughout the quarter.


LIQUIDITY AND CAPITAL RESOURCES


The Company had a cash balance of $1 as of March 31, 2008. Accounts receivable as of March 31, 2008 was $822. It is estimated that it will require outside capital for the remainder of fiscal year 2008 for the commercialization of GeneThera's molecular assays as well as the development of their therapeutic vaccines. The Company intends to raise these funds by means of one or more private offerings of debt or equity securities or both and also generating revenue from Mexico.  Currently the company is in discussions with one group to obtain financing through either debt and/or equity.  No definitive agreements have been signed.  There are no guarantees whether the Company will be able to secure such a financing, and if the financing is secured, there are no guarantees whether the Company can achieve the goals laid out in its business plan fully. We will require significant additional funding in order to achieve our business plan.


Our longer-term working capital and capital requirements will depend upon numerous factors, including revenue and profit generation, pre-clinical studies and clinical trials, the timing and cost of obtaining regulatory approvals, the cost of filing, prosecuting, defending, and enforcing patent claims and other intellectual property rights, competing technological and market developments, collaborative arrangements.  Additional capital will be required in order to attain such goals.  Such additional funds may not become available on acceptable terms and we cannot give any assurance that any additional funding that we do obtain will be sufficient to meet our needs in the long term.


 Item 3.  GENETHERA PLAN OF OPERATION


Background


In November 2007, GeneThera, Inc. reincorporated in the State of Nevada due to a third party which purchased the GeneThera Florida Charter in order to blackmail our Company for $80,000. We had a special meeting with three shareholders where it was unanimously resolved for GeneThera to transfer its Charter to the State of Nevada as soon as possible in order to recognize our new incorporation on our next SEC filing. The reinstatement was completed by January 2008. GeneThera has developed proprietary diagnostic assays for use in the agricultural and veterinary markets. Specific assays for Chronic Wasting Disease (among elk and deer) and Mad Cow Disease (among cattle) have been developed and are available currently on a limited basis.  E.coli (predominantly cattle) and Johne's disease (predominantly dairy cattle and bison) diagnostics are in development.


GeneThera provides genetics-based diagnostic and is currently working on vaccine solutions to meet the growing demands of today's veterinary industry and tomorrow's agriculture and healthcare industries. The company is organized and operated both to continually apply its scientific research to more effective management of diseases and, in so doing, realize the commercial potential of molecular biotechnology.


The Company believes it will require significant additional funding in order to achieve its business plan.  Over the next 12 months, in order to have the capability of achieving its business plan, the Company will require at least $5,000,000.  There are no guarantees whether the Company will be able to secure such a financing, and if the financing is secured, there are no guarantees whether the Company can achieve the goals laid out in its business plan fully.


RESEARCH AND DEVELOPMENT


We anticipate that research and development (R&D) will be the source for both assay development and vaccine design/development.  If we are able to develop assays for different diseases, we intend to formalize the procedure into a commercial application through a series of laboratories to be owned and operated by GeneThera.  To date, we have introduced our diagnostic solution for Chronic Wasting Disease and Mad Cow Disease on a very limited basis.  We anticipate that R&D will be ongoing during the life of the Company, as this is the source for new products to be introduced to the market.  Our plan is to seek new innovations in the biotechnology field. We cannot assure you that we will be successful in developing or validating any new assays or, if we are successful in developing and validating any such assays, that we can successfully commercialize them or earn profits from sales of those assays.  Furthermore, we cannot assure you that we will be able to design, develop, or successfully commercialize any vaccines as a result of our research and development efforts.


COMMERCIAL DIAGNOSTIC TESTING


In the event that we are able to develop assays for the detection of diseases in animals, we intend to establish a series of diagnostic testing laboratories geographically proximate to the primary sources of individual diseases and/or according to specific available operating efficiencies.  The specific number of labs to be built and operated will be based on assay demand (demand facilitated by the number of specific disease assays GeneThera develops), our ability to obtain the capital to build the labs, and our ability to successfully manage them from our principal office.  As of the date of this filing, we are in negotiation to establish one diagnostic testing laboratory outside of our Colorado facility.



LICENSING


Through our third division, Licensing, we intend to manage the marketing and sale of the vaccines developed by GeneThera's Research & Development division.  As GeneThera does not intend to be a vaccine manufacturer, we plan to use our Licensing division to license the technology related to any vaccines that may be developed and to manage the revenue potential available from the successful development and validation of specific vaccines.  We cannot provide any assurance that we will develop any vaccines or that, if they are developed, we will be able to license them successfully or that any such license will produce significant revenues.



R&D SERVICES


Molecular, Cellular, Viral Biology Research, and Consulting Services.  We  provide independent research services to scientists in academia, the pharmaceutical industry, and the biotechnology industry.  Primarily, GeneThera's expertise focuses on technology relevant to animal and human immunotherapy.  These services are backed by the cumulative experiences of greater than 50 years of research and development in both government and industry by GeneThera's senior scientists. GeneThera intends to develop a commercial-scale implementation of Adenovector Purification Process to support R&D material production.  Furthermore, GeneThera intends to evaluate and test commercially available expression vectors and incorporate them into its vector repertoire.  These technologies are well established within the repertoire of GeneThera's scientific staff.  We cannot provide any assurance, however, that we will be able to successfully offer these services or that, if offered, we can provide them profitably.


Research & Development Services:


Molecular Biology:


Synthetic cDNA Construction

Prokaryotic Expression Vector Construction & Development

E.coli Expression Strain Evaluation

Pilot Scale Fermentation

Mammalian Expression Vector Construction & Development

Baculovirus Expression

Protein Isolation

Protein Engineering: Complement Determining Region Conjugated Proteins

Monoclonal Antibody Production Chimerization & Humanization

Vector design for Prokaryotic Expression of Antibody Fragments (Fab) and Single Chain Antibody (ScFv)


Pilot Scale-up Development


Process Purification & Characterization

Assay Development & Quality Control Pharmaceutical Dosage and Formulation






Gene Therapy Testing Services. GeneThera offers GLP (Good Laboratory Procedure) testing programs for somatic cell, viral and naked DNA-based gene therapies.  Our scientists have over nine years experience in providing fully integrated bio-safety testing programs for the cell and gene therapy fields.  To date, the Company has not generated any revenues with regard to these services, and there is no assurance that we will generate any revenues from such services.


Replication-Competent Viral Vector Testing.  Sensitive in vitro cell culture assays are used to detect replication-competent retroviruses or adenoviruses.  GeneThera can work with clients to provide custom replication-competent virus detection assays for the particular vector construct.


Complete Somatic Cell and Viral Vector Packaging and Producer Cell Line Characterization.  GeneThera offers all of the assays mandated by regulatory authorities worldwide for the bio-safety analysis and characterization of cells and cell lines used in gene therapy products.


Vector Stock Characterization.  Custom purity and potency testing is available for gene therapy viral ector stocks.


Vector Purification Process Validation for Viral Clearance.  Most biopharmaceuticals require viral clearance studies to validate the removal of potential contaminants, such as those from bovine components or from helper viruses (adenovirus in AAV production).  GeneThera can provide custom design and performance of viral studies for various vector purification processes.


Custom Bio-safety Testing Programs for Somatic Cell, Ex Vivo Cell, and Tissue Therapies.  GeneThera can guide our clients through the unique process of designing and implementing a bio-safety testing program that meets the needs of each specific project.


GeneThera is currently seeking contracts for these services and is in the final negotiation stage with a publicly traded company to perform these services on an annual basis.  There is no assurance that any contracts will be signed or that the company will generate significant revenues or profits from any such contracts.


BUSINESS MODEL


Summary.  GeneThera's animal disease assay development business is based on its Integrated Technology Platform (ITP) that combines a proprietary diagnostic solution called Gene Expression Assay (GES) with PURIVAXTM, its system for analyzing large-scale DNA sequencing.  The first part of this platform is the ongoing development of molecular diagnostic assays solutions using real time Fluorogenic Polymerase Chain Reaction (F-PCR) technology to detect the presence of infectious disease from the blood of live animals.  The second part of the ITP is the development of therapeutic vaccines using RNA interference technology.  It also allows for the efficient, effective, and continuous testing, management and treatment of animal populations.  These facts distinguish the technology from any alternative testing and management methodology available to agriculture today -- all of which require the destruction of individual animals and even entire herds.  Our testing and data analysis processes also allow us not only to separate infected from clean animals, but also to gain knowledge vital to development of preventative vaccines.


Each individual assay utilizes the proprietary Field Collection System (FCS) for the collection and transportation of blood samples to GeneThera's laboratory.  The FCS allows GeneThera to maintain the integrity of each sample by the addition of specific reagents to test tubes contained in the system.  GeneThera's FCS is designed to be an easy-to-use method of gathering blood samples from harvested or domesticated animals.  It ensures consistency of samples as well as increased assurance of each sample's integrity.


To date, GeneThera has successfully developed the ability to detect Chronic Wasting Disease, a disease affecting elk and deer in North America.  The release of commercialized Field Collection Systems and laboratory diagnostic testing occurred in October of 2003 as a marketing trial.  GeneThera has also successfully developed an assay for the detection of Mad Cow Disease, a disease recently found in the United States, but which has been in Europe for many years.  The Field Collection Systems are available for purchase from the Company.  Chronic Wasting Disease and Mad Cow Disease are both in the family of diseases called Transmissible Spongiform Encephalopathy (TSE).  Diagnostic assays for E.coli O157:H7 and Johne's disease are in the final stages of development.


The Company, through GeneThera, is also developing vaccines for Chronic Wasting Disease and E.coli O157:H7.  The Company will need the approval of the USDA before the vaccines can be manufactured or sold.  The approval process for animal vaccines is time-consuming and expensive.  We anticipate that such approval, if it is obtained, may require more than $5 million and may require more than two years for each vaccine for which approval is sought.  Currently we do not have the capital necessary to seek approval of any of our candidate vaccines, and we cannot provide any assurance that we will be able to raise the capital necessary for such approval on terms that are acceptable to us, if at all.  In addition, even if we are successful in raising the capital necessary to seek approval of any vaccine, there are no assurances that such an approval will be granted, or if granted, whether we will be able to produce and sell such vaccines following such an approval in commercial quantities or to make a profit from such production and sales.








ITEM 4.

CONTROLS AND PROCEDURES.


As required by Rule 13a-15 under the Securities Exchange Act of 1934 (the "Exchange Act"), we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures within the 90 days prior to the filing date of this report. These evaluations was carried out under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer are effective in timely alerting management to material information relating to us that is required to be included in our periodic SEC filings.

There have been no significant changes in our internal controls or in other factors that could significantly affect internal controls subsequent to the date we carried out our evaluation.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms.  Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.



PART II - OTHER INFORMATION


Item 1.     Legal Proceedings


On or about July 23, 2004, Sisu Media sued the Company in Jefferson County District Court for breach of an alleged contract for website services for which the plaintiff seeks compensatory damages, plus costs, interest, and attorney’s fees in amounts to be determined at trial.  Trial was held on August 4, 2005, wherein the court determined that Sisu Media was entitled to compensation based only upon the breach of contract claim. Plaintiff’s claims in quantum meruit and for unjust enrichment were dismissed. The court also dismissed defendant GeneThera, Inc.’s claim of aiding and abetting a breach of fiduciary duty by third party. Entry of judgment was entered in favor of the plaintiff in the amount of $49,000.00. On February 9, 2006, the Company appealed this judgment and on January 9, 2008, the Appellate Committee’s decision was in favor of the plaintiff due to lack of adequate legal representation. An additional judgment of $6,237.31 was awarded for their attorney’s fees. The Company has not paid the abovementioned judgment(s).


On October 11, 2006, MAG Capital, a California Limited Liability Company (Mercator Momentum III, LP; Mercator Momentum Fund LP; Monarch Pointe Fund, Ltd; a British Virgin Islands Corporation), filed litigation against GeneThera, Inc., GTI Corporate Transfer Agents, LLC, a Colorado limited liability company, Antonio Milici, an individual, Tannya L. Irizarry, and Laura Bryan, individuals in the Superior Court State Complaint for breach of written contract. The Company retained legal counsel from Mark A. Shoemaker. In January 2008, MAG Capital dismissed the claims except the anticipatory breach of contract for which the Company’s legal counsel filed an appeal dated February 19, 2008.


Item 2.     Changes in Securities


None.


Item 3.     Defaults upon Senior Securities


No defaults upon senior securities.


Item 4.     Submission of Matters to a Vote of Security Holders


No matters were submitted to a vote of security holders as of March 31, 2008.  


Item 5.     Other Information


None.


Item 6.     Exhibits and Reports on Form 10-Q


(A)       Financial Statements


Reference is made to the financial statements listed on the Index to Financial Statements in this Form 10-Q.


(B)

Exhibits

 

 


A.1

(31.1) Certification pursuant to section 302 of the Sarbanes-Oxley act of 2002

A.2

(31.2) Certification pursuant to section 302 of the Sarbanes-Oxley act of 2002

             (99.1)  Certification of the President and Chief Executive Officer

             (99.2)  Certification of the Chief Financial Officer


Signatures


Pursuant to the requirements of the Securities Act of 1933 the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Wheat Ridge, Colorado on this 20th day of May, 2008.GENETHERA, INC.

By:  s/ Antonio Milici
Name:   Antonio Milici
Title:  President and Chief Executive Officer


Pursuant to the requirements of the Securities Act of 1933 this Registration Statement has been signed by the following persons in the capacities indicated on May 20, 2007:

Signature

Title(s)


/s/ Antonio Milici

Antonio Milici


President, Chief Executive Officer and Director
(principal executive officer)


/s/ Tannya L Irizarry
Tannya L Irizarry


Chief Financial Officer (Interim)

/s/ Thomas Slaga
  Thomas Slaga

 Director